Kyongbo Pharmaceutical CoXKRX:214390 +1.58%80 Operating Margin % is 1.08% as of Mar. 2026, which is 70% below its 10-year median of 3.63. GuruFocus rates XKRX:214390 with a GF Score™ of 80/100 and a GF Value™ of ₩8,990.31 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 961 Drug Manufacturers companies, Kyongbo Pharmaceutical Co ranks worse than 66.18% on this metric.
The historical rank and industry rank for Kyongbo Pharmaceutical Co's Operating Margin % or its related term are showing as below:
XKRX:214390'
s Operating Margin % Range Over the Past 10 Years
Min: -3.88 Med: 3.63 Max: 12.83
Current: 1.52
XKRX:214390's Operating Margin % is ranked worse than 66.18% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.57
vs XKRX:214390: 1.52
Kyongbo Pharmaceutical Co (XKRX:214390) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Kyongbo Pharmaceutical Co Operating Margin % Related Terms
Kyongbo Pharmaceutical Co Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyongbo Pharmaceutical Co Operating Margin % Chart
XKRX:214390 vs ZTS, UTHR: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyongbo Pharmaceutical Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyongbo Pharmaceutical Co Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyongbo Pharmaceutical Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Kyongbo Pharmaceutical Co's Operating Margin % falls into.
Kyongbo Pharmaceutical Co Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Kyongbo Pharmaceutical Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyongbo Pharmaceutical Co (XKRX:214390) has a Operating Margin % of 1.08% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Kyongbo Pharmaceutical Co and its competitors. This is 70% below median its historical median of 3.63. According to the industry distribution chart, Kyongbo Pharmaceutical Co ranks #636 out of 961 companies in the Drug Manufacturers industry, placing it in the top 66.2%.
Is Kyongbo Pharmaceutical Co's Operating Margin % too high?
Kyongbo Pharmaceutical Co's current Operating Margin % of 1.08% is 70% below median its 10-year median of 3.63. The Drug Manufacturers industry median Operating Margin % is 7.57. Kyongbo Pharmaceutical Co's value of 1.08% is 85.7% below this industry median. Based on the distribution chart, Kyongbo Pharmaceutical Co ranks #636 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kyongbo Pharmaceutical Co has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kyongbo Pharmaceutical Co's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyongbo Pharmaceutical Co ranks #636 out of 961 companies for Operating Margin %. This places Kyongbo Pharmaceutical Co in the lower half of its industry. The industry median Operating Margin % is 7.57. Kyongbo Pharmaceutical Co's value of 1.08% is 85.7% below this benchmark. While the company's 10-year median is 3.63 vs. the industry median of 7.57, Kyongbo Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.57, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyongbo Pharmaceutical Co's current Operating Margin % of 1.08% is 85.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Kyongbo Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyongbo Pharmaceutical Co's current Operating Margin % is 1.08%, which is 70% below median its own 10-year median of 3.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyongbo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyongbo Pharmaceutical Co (XKRX:214390) is currently considered Possible Value Trap. The stock's GF Value™ is ₩8,990.31, compared to a current price of ₩5,150.00 — trading 42.7% below its estimated fair value. The current Operating Margin % is 1.08%, which is 70% below median its 10-year median of 3.63 and 85.7% below the Drug Manufacturers industry median of 7.57. Kyongbo Pharmaceutical Co's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Kyongbo Pharmaceutical Co (XKRX:214390), the current Operating Margin % is 1.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyongbo Pharmaceutical Co (XKRX:214390) Overvalued in 2026?
Based on GuruFocus' analysis, Kyongbo Pharmaceutical Co stock appears to be undervalued.
The current stock price of ₩5,150.00 is trading 42.7% below its estimated GF Value™ of ₩8,990.31.
GuruFocus considers Kyongbo Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for XKRX:214390:
Operating Margin %: 1.08% (70% below median its 10-year median of 3.63)
GF Value™: ₩8,990.31 vs. price of ₩5,150.00 (42.7% below fair value)
Industry Position: 85.7% below the Drug Manufacturers median (#636 of 961)
No single metric tells the full story. See the XKRX:214390 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyongbo Pharmaceutical Co Ltd is a pharmaceutical company. It is involved in the business of manufacturing and sales of active pharmaceutical ingredients and finished drugs. The company is actively engaged in animal health businesses, including medical devices, veterinary medicines, and nutritional supplements.
80GF Score
Get the complete analysis for XKRX:214390
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:214390 has been successfully added to your 
